fashion -WSS

fashion

author：comprehensive 2025-09-30 23:19:26 - browse：137

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： EU fines Illumina $475 million over Grail acquisition

focus

leisure time

WSS

AI gets buy

Global cancer cases to surge 77% by 2050, WHO report says

Gene therapy for Afghan refugees’ infant will be fully covered

EU fines Illumina $475 million over Grail acquisition

Global cancer cases to surge 77% by 2050, WHO report says

Padmanee Sharma of MD Anderson at center of lawsuit over credit

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

What does generative AI mean for health care? We asked experts

Why Novartis is going to walk from its acquisition of MorphoSys

Affirmative action in medical school literally saved lives

Cano Health’s bankruptcy is a warning for Medicare Advantage

Bright Health sells Medicare Advantage business to Molina

Is there an 'orca uprising'? Like orcas themselves, the answer is complex.

Bright Health sells Medicare Advantage business to Molina

Global cancer cases to surge 77% by 2050, WHO report says

Hepatitis C has a cure — but many Americans still lack access to it

Readout LOUD: Venture capital, Gilead, and more M&A

leisure time

Rapinoe says her retirement call will help US women's soccer team to focus at World Cup

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

A protest over insulin prices is seen as a fight for life

After half a century, Israel moves to evict squatter from his cave home on the beach

focus

leisure time

focus

hotspot